**Executive Summary**
NITI Aayog has launched a ten-year roadmap to transform India into a global bioeconomy powerhouse, targeting a valuation of $691 billion by 2035 and $2.6 trillion by 2047. The strategy focuses on high-performance biomanufacturing, the creation of 30 million high-value jobs, and the convergence of AI with biology. Key action items include the establishment of six National BioMissions and the proposal of a ₹50,000 crore BioEconomy Growth Fund to drive commercialization and infrastructure development.
**Key Points / Main Content**
* **Economic Objectives and Growth Targets**
* Scale the BioEconomy from $195.3 billion (4.8% of GDP in 2025) to $691 billion by 2035 and $2.6 trillion by 2047.
* Position India as a leading global biotechnology power and a trusted hub for biomanufacturing.
* Generate over 30 million high-value jobs through the expansion of the biotechnology ecosystem.
* **National BioMissions (Execution Platforms)**
* Implementation of six focused missions: GeneIndia, AgriBio 2.0, BioX Foundry, One Health Grid, Marine Biotechnology, and BioPharmaNext.
* Development of scalable capabilities in healthcare, climate-resilient crops, blue economy, and pandemic preparedness.
* Advancement of affordable cell and gene therapies, biosimilars, vaccines, and next-generation therapeutics.
* **Technological Convergence and Innovation**
* Integration of Artificial Intelligence (AI) with biology to accelerate discovery and reduce costs.
* Utilization of computational biology, digital twins, robotics, and AI-driven "Design-Build-Test-Learn" platforms.
* Focus on programmable biology to shape the rules and platforms of the emerging "biological age."
* **Financial and Infrastructure Support**
* Proposal to carve out a ₹50,000 crore BioEconomy Growth Fund from the existing ₹1 lakh crore RDI framework.
* Funding directed toward scale-up, commercialization, fermentation platforms, and synthetic biology.
* Investment in biomanufacturing infrastructure, biomaterials, and advanced diagnostics.
**Impact Analysis**
**Government and Policy Makers**
* **Impact:** Required to shift from incremental innovation to a mission-mode strategy involving multiple departments.
* **Action Required:** Oversee the implementation of the six National BioMissions and manage the proposed ₹50,000 crore Growth Fund.
**Industry and Entrepreneurs**
* **Impact:** Enhanced opportunities for global competitiveness through advanced biomanufacturing and stronger industry linkages.
* **Action Required:** Scale up operations, invest in AI-driven discovery platforms, and move from discovery to deployment of new products and technologies.
**Academia and Research Institutions**
* **Impact:** Increased focus on translating scientific innovation into scalable national capabilities.
* **Action Required:** Partner with government and industry to conduct research in high-performance biomanufacturing and programmable biology.
**Workforce and Job Seekers**
* **Impact:** Significant expansion of the job market with the projected creation of 30 million high-value positions.
* **Action Required:** Acquire specialized skills in emerging fields such as computational biology, synthetic biology, and advanced bioprocessing.
Key Entities Referenced
Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035: A mission-mode strategic document launched by NITI Aayog to scale India's bioeconomy to $691 billion by 2035 and $2.6 trillion by 2047.
National BioMissions: Six execution platforms including GeneIndia, AgriBio 2.0, BioX Foundry, One Health Grid, Marine Biotechnology, and BioPharmaNext designed to scale biotechnology capabilities.
BioEconomy Growth Fund: A proposed ₹50,000 crore fund intended to support scale-up, commercialization, and infrastructure for advanced therapeutics and synthetic biology.
BioE3 Policy: A foundational policy framework focused on Biotechnology for Economy, Environment, and Employment that provides the vision for India's biomanufacturing hub.
Department of Biotechnology: The primary government department that co-developed the roadmap and oversees the national biotechnology innovation and deployment ecosystem.
NITI Aayog
NITI Aayog launches a ten-year roadmap to build
India into a leading bioeconomy powerhouse by
2035
NITI roadmap sets a pathway to establish India as a $2.6
trillion Bio Economy by 2047
प्रव तथ: 16 JUL 2026 6:30PM by PIB Delhi
NITI Aayog launched the “Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035”
at the National Media Centre, New Delhi. Developed by NITI Frontier Tech Hub in consultation with the
Department of Biotechnology, Association of Biotechnology Led Enterprises (ABLE), industry, academia
and other stakeholders, the roadmap sets out a mission-mode strategy to position India as a leading global
bioeconomy powerhouse by 2035.
The roadmap was launched by Dr. Jitendra Singh, Minister of State (Independent Charge), Ministry of
Science & Technology, in the presence of Prof. Gobardhan Das, Member, NITI Aayog; Smt. Nidhi
Chhibber, CEO, NITI Aayog; Shri Rajesh S. Gokhale, Secretary, Department of Biotechnology; Ms.
Debjani Ghosh, Distinguished Fellow, NITI Aayog; and Mr. G. S. Krishnan, President, ABLE.
Biotechnology is emerging as one of the most important engines of India’s next phase of growth. Just as
digital technologies transformed information, biotechnology is now beginning to transform how the world
produces medicines, food, fuels, chemicals, materials and climate-resilient solutions. India has a time-
bound opportunity to move from being a trusted global supplier of affordable healthcare products to
becoming a leading global bioeconomy powerhouse.
India enters this decade with strong foundations. The country’s BioEconomy has expanded from $10
billion in 2014 to $195.3 billion in 2025, contributing 4.8% to national GDP. The roadmap lays out a
strategy to scale this to $691 billion by 2035 and $2.6 trillion by 2047, while creating over 30 million
high-value jobs and positioning India among the world’s leading biotechnology powers.
Speaking on the occasion, Dr. Jitendra Singh said: “India’s bioeconomy has grown from about $10 billion
in 2014 to over $195 billion today, reflecting the strength of our scientists, entrepreneurs and
biotechnology ecosystem. The next phase of this journey must be about translating innovation into impact
at scale—through high-performance biomanufacturing, stronger industry linkages and new opportunities
across healthcare, agriculture, climate solutions and sustainable manufacturing. This Roadmap provides a
timely pathway to build on the vision of the BioE3 Policy and strengthen India’s emergence as a global
biotechnology and biomanufacturing hub.”
Prof. Gobardhan Das, Member, NITI Aayog observed: "The coming decade will determine whether India
shapes the global bioeconomy or is shaped by it. With world-class scientific talent, proven manufacturing
capabilities, and a bold national roadmap, India is uniquely positioned to lead the biological century.Realizing this vision will require a strong partnership between government, industry, academia, and
investors to transform innovation into global impact.”
Shri Rajesh S. Gokhale, Secretary, Department of Biotechnology emphasised: “India's next bioeconomy
leap must go beyond incremental innovation. The real opportunity lies in creating entirely new
technologies, products and industries, and taking them from discovery to deployment at scale. By
combining entrepreneurship with advanced biomanufacturing, India can build globally competitive
enterprises and help define the future of the biological age.”
Ms. Debjani Ghosh, Distinguished Fellow, NITI Aayog noted: “Artificial intelligence has emerged as one
of the most disruptive general-purpose technologies of our time. But alongside it, another transformation
of equal and perhaps even greater significance is taking shape: the rise of programmable biology. We
believe the Bio Century will be one of the defining shifts of the next decade. India now has a historic
opportunity to move early and help shape the rules, markets and platforms of this emerging biological
age.”
A central recommendation is the creation of six National BioMissions as focused execution platforms for
India’s next phase of bioeconomy growth. GeneIndia, AgriBio 2.0, BioX Foundry, One Health Grid,
Marine Biotechnology and BioPharmaNext are designed to convert India’s scientific and manufacturing
strengths into scalable national capabilities across health, agriculture, industrial biotechnology, pandemic
preparedness, blue economy and next-generation biopharma. Together, they aim to advance affordable cell
and gene therapies, climate-resilient crops and bio-inputs, AI-enabled biofoundries, integrated disease
surveillance, marine bio-products and advanced biomanufacturing of biologics, biosimilars, vaccines and
next-generation therapeutics.
A major thrust is the convergence of AI and biology. The roadmap highlights the need for computational
biology, biofoundries, digital twins, biosensor networks, robotics and AI-driven Design-Build-Test-Learn
platforms to accelerate discovery, reduce costs and enable India to compete in next-generation
biotechnology and biomanufacturing.
A key proposal is to carve out a ₹50,000 crore BioEconomy Growth Fund from within the existing ₹1
lakh crore RDI framework. The proposed fund would support scale-up, commercialization,
biomanufacturing infrastructure, advanced therapeutics, fermentation platforms, biomaterials, diagnostics
and synthetic biology.
The launch event was attended by senior officials from Government of India, representatives from
industry, academia, startups, research institutions and other stakeholders from the biotechnology
ecosystem.
The full roadmap can be accessed here: https://niti.gov.in/sites/default/files/2026-07/Roadmap-for-Buildin
g-India-as-a-Leading-Bioeconomy-Powerhouse.pdf
****
MJPS/SS/PRK
(रलीज़ आईडी: 2285858) आगंतुक पटल : 177